Market Overview

Aurora Cannabis COO Specifies Why Company's Product Sales Are Halted In Germany

Aurora Cannabis COO Specifies Why Company's Product Sales Are Halted In Germany

Germany recently halted Aurora Cannabis (NYSE: ACB) product sales, until the health authorities investigate the production process.

The production step awaiting for the inspection is related to a method that Aurora utilizes to attain a long shelf life of the flower, German pharmacies reportedly said.

Aurora COO Cam Battley said at the Marijuana Business Daily's Investor Intelligence Conference that the sales were paused over “a form of treatment that we use to maintain the product without microbial contamination."

“We realized we needed a permit,” Battley said, adding that “obviously, we’re a little red faced on that. Nobody likes an operational hiccup.”

Battley was alluding to the special permit that's demanded for distribution of irradiated medical cannabis products in Germany, adding “it’s going to take about four weeks” for the company to acquire it, according to Marijuana Business Daily.

The company’s CEO also shared his belief that Aurora will “win” the German market once it resolves the current issue.

Aurora’s stock traded at $2.45 per share on Thursday.

Related Links:

Aurora's CBD Oil Approved As Medical Marijuana Product In Ireland

Aurora Cannabis Analyst Says Company Poised To Outperform Canadian Peers

Posted-In: Cam Battley Germany Marijuana Business DailyCannabis News Global Markets Media Best of Benzinga


Related Articles (ACB)

View Comments and Join the Discussion!

Cannabis Movers

Sign up for our secret cannabis newsletter!
Never miss out on the breaking news in the Cannabis Industry!